Daniele Piomelli

List of Publications by Year
in descending order

203 papers	21,349 citations	18482 62 h-index	9589 142 g-index
216 all docs	216 docs citations	216 times ranked	13274 citing authors

#	Article	IF	Citations
1	The endocannabinoid system in the adipose organ. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 51-60.	5.7	12
2	Endocannabinoid-Based Therapies. Annual Review of Pharmacology and Toxicology, 2022, 62, 483-507.	9.4	32
3	Persistent sexually dimorphic effects of adolescent THC exposure on hippocampal synaptic plasticity and episodic memory in rodents. Neurobiology of Disease, 2022, 162, 105565.	4.4	7
4	Comparative Pharmacokinetics of Î”⁹-Tetrahydrocannabinol in Adolescent and Adult Male and Female Rats. Cannabis and Cannabinoid Research, 2022, 7, 814-826.	2.9	11
5	Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity. Metabolism: Clinical and Experimental, 2022, 131, 155181.	3.4	3
6	Frequent Low-Dose Î”9-Tetrahydrocannabinol in Adolescence Disrupts Microglia Homeostasis and Disables Responses to Microbial Infection and Social Stress in Young Adulthood. Biological Psychiatry, 2022, 92, 845-860.	1.3	18
7	Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. Pharmacological Research, 2022, 182, 106338.	7.1	2
8	N-acylethanolamine acid amidase (NAAA) inhibition decreases the motivation for alcohol in Marchigian Sardinian alcohol-preferring rats. Psychopharmacology, 2021, 238, 249-258.	3.1	6
9	Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. Neurobiology of Disease, 2021, 147, 105157.	4.4	29
10	Pharmacokinetic, behavioral, and brain activity effects of Î”9-tetrahydrocannabinol in adolescent male and female rats. Neuropsychopharmacology, 2021, 46, 959-969.	5.4	51
11	NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranes. Advances in Pharmacology, 2021, 90, 217-238.	2.0	3
12	Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1410-1422.	5.2	5
13	Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects. Journal of the National Cancer Institute Monographs, 2021, 2021, 78-85.	2.1	7
14	Impact of Circulating <i>N</i>-Acylethanolamine Levels with Clinical and Laboratory End Points in Hemodialysis Patients. American Journal of Nephrology, 2021, 52, 59-68.	3.1	1
15	Ablation of Acid Ceramidase Impairs Autophagy and Mitochondria Activity in Melanoma Cells. International Journal of Molecular Sciences, 2021, 22, 3247.	4.1	14
16	Antinociceptive Profile of ARN19702, (2-Ethylsulfonylphenyl)-[(2S)-4-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazin-1-yl]methanone, a Novel Orally Active N-Acylethanolamine Acid Amidase Inhibitor, in Animal Models. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 70-76.	2.5	4
17	Hypothalamic hormone-sensitive lipase regulates appetite and energy homeostasis. Molecular Metabolism, 2021, 47, 101174.	6.5	11
18	Acid ceramidase controls apoptosis and increases autophagy in human melanoma cells treated with doxorubicin. Scientific Reports, 2021, 11, 11221.	3.3	17

#	Article	IF	Citations
19	Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain. Pharmacological Research, 2021, 167, 105545.	7.1	13
20	Persistent Exposure to Î”⁹-Tetrahydrocannabinol during Adolescence Does Not Affect Nociceptive Responding in Adult Mice. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 215-221.	2.5	3
21	Frequent Î”9- tetrahydrocannabinol exposure during adolescence impairs sociability in adult mice exposed to an aversive painful stimulus. European Neuropsychopharmacology, 2021, 53, 19-24.	0.7	3
22	Pancreatic Painâ€"Knowledge Gaps and Research Opportunities in Children and Adults. Pancreas, 2021, 50, 906-915.	1.1	6
23	NAAA-regulated lipid signaling governs the transition from acute to chronic pain. Science Advances, 2021, 7, eabi8834.	10.3	15
24	Ceramide contributes to pathogenesis and may be targeted for therapy in VCP inclusion body myopathy. Human Molecular Genetics, 2021, 29, 3945-3953.	2.9	10
25	FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. Neurobiology of Disease, 2020, 134, 104624.	4.4	33
26	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. European Journal of Medicinal Chemistry, 2020, 189, 112047.	5.5	8
27	N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations. ACS Catalysis, 2020, 10, 11797-11813.	11.2	13
28	Comparative Pharmacokinetics of Î”⁹-Tetrahydrocannabinol in Adolescent and Adult Male Mice. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 151-160.	2.5	56
29	Cannabinoid CB2 receptors mediate the anxiolytic-like effects of monoacylglycerol lipase inhibition in a rat model of predator-induced fear. Neuropsychopharmacology, 2020, 45, 1330-1338.	5.4	30
30	N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition. Journal of Medicinal Chemistry, 2020, 63, 7475-7490.	6.4	54
31	N-Acylethanolamine Acid Amidase contributes to disease progression in a mouse model of multiple sclerosis. Pharmacological Research, 2020, 160, 105064.	7.1	14
32	Next Stop for Fatty Acid Amide Hydrolase Inhibitors, the Clinic?. Biological Psychiatry, 2020, 87, 485-486.	1.3	1
33	Inhibition of fatty acid amide hydrolase in the CNS prevents and reverses morphine tolerance in male and female mice. British Journal of Pharmacology, 2020, 177, 3024-3035.	5.4	16
34	Exposure to the cannabinoid agonist WIN 55, 212â€"2 in adolescent rats causes sleep alterations that persist until adulthood. European Journal of Pharmacology, 2020, 874, 172911.	3.5	10
35	Circulating Endocannabinoids and Mortality in Hemodialysis Patients. American Journal of Nephrology, 2020, 51, 86-95.	3.1	9
36	The Synthetic Cannabinoid URB447 Reduces Brain Injury and the Associated White Matter Demyelination after Hypoxia-Ischemia in Neonatal Rats. ACS Chemical Neuroscience, 2020, 11, 1291-1299.	3.5	11

#	Article	IF	Citations
37	Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy. Radiation Research, 2020, 193, 407.	1.5	12
38	Cannabinoids in periodontal disease amid the COVID-19 pandemic. Journal of Periodontal and Implant Science, 2020, 50, 355.	2.0	1
39	It is DÃ©jÃ Vu All Over Again. Cannabis and Cannabinoid Research, 2019, 4, 73-74.	2.9	0
40	Waiting for the Entourage. Cannabis and Cannabinoid Research, 2019, 4, 137-138.	2.9	7
41	A protective role for N-acylphosphatidylethanolamine phospholipase D in 6-OHDA-induced neurodegeneration. Scientific Reports, 2019, 9, 15927.	3.3	25
42	Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats. Journal of Pharmacy and Pharmacology, 2019, 71, 1762-1773.	2.4	9
43	Feeding Stimulates Sphingosine-1-Phosphate Mobilization in Mouse Hypothalamus. International Journal of Molecular Sciences, 2019, 20, 4008.	4.1	3
44	Fast and Sensitive Quantification of Î”⁹-Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry. Cannabis and Cannabinoid Research, 2019, 4, 110-123.	2.9	24
45	Diurnal Profiles of N-Acylethanolamines in Goldfish Brain and Gastrointestinal Tract: Possible Role of Feeding. Frontiers in Neuroscience, 2019, 13, 450.	2.8	7
46	Regulatory Barriers to Research on Cannabis and Cannabinoids: A Proposed Path Forward. Cannabis and Cannabinoid Research, 2019, 4, 21-32.	2.9	12
47	Mast Cell-Derived Histamine Regulates Liver Ketogenesis via Oleoylethanolamide Signaling. Cell Metabolism, 2019, 29, 91-102.e5.	16.2	33
48	Familial abnormalities of endocannabinoid signaling in schizophrenia. World Journal of Biological Psychiatry, 2019, 20, 117-125.	2.6	26
49	Elevated plasma ceramide levels in post-menopausal women: a cross-sectional study. Aging, 2019, 11, 73-88.	3.1	36
50	Inhibition of de novo ceramide biosynthesis affects aging phenotype in an in vitro model of neuronal senescence. Aging, 2019, 11, 6336-6357.	3.1	9
51	Peripheral Endocannabinoids Associated With Energy Expenditure in Native Americans of Southwestern Heritage. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1077-1087.	3.6	17
52	Atypical Endocannabinoid Signaling Initiates a New Form of Memory-Related Plasticity at a Cortical Input to Hippocampus. Cerebral Cortex, 2018, 28, 2253-2266.	2.9	50
53	The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of AllergicÂDermatitis. Journal of Investigative Dermatology, 2018, 138, 562-569.	0.7	41
54	Inhibition of monoacylglycerol lipase: Another signalling pathway for potential therapeutic targets in migraine?. Cephalalgia, 2018, 38, 1138-1147.	3.9	12

#	Article	IF	Citations
55	Endocannabinoid Anandamide Mediates the Effect of Skeletal Muscle Sphingomyelins on Human Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3757-3766.	3.6	6
56	Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety. Psychopharmacology, 2018, 235, 3211-3221.	3.1	38
57	Molecular mechanism of activation of the immunoregulatory amidase NAAA. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10032-E10040.	7.1	36
58	Endocannabinoid System and Migraine Pain: An Update. Frontiers in Neuroscience, 2018, 12, 172.	2.8	48
59	Cannabis and the Opioid Crisis. Cannabis and Cannabinoid Research, 2018, 3, 108-116.	2.9	10
60	Pleiotropic Effect of Human ApoE4 on Cerebral Ceramide and Saturated Fatty Acid Levels. Journal of Alzheimer's Disease, 2017, 60, 769-781.	2.6	7
61	Neurophysiology of space travel: energetic solar particles cause cell type-specific plasticity of neurotransmission. Brain Structure and Function, 2017, 222, 2345-2357.	2.3	47
62	Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. Neuropharmacology, 2017, 124, 3-12.	4.1	64
63	Endocannabinoid Signaling in the Control of Social Behavior. Trends in Neurosciences, 2017, 40, 385-396.	8.6	76
64	Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome. Pharmacological Research, 2017, 117, 75-81.	7.1	16
65	Novel activity-based probes for N-acylethanolamine acid amidase. Chemical Communications, 2017, 53, 11810-11813.	4.1	7
66	Expert Panel on Understanding Cannabis: Medicine, Society, Government. Cannabis and Cannabinoid Research, 2017, 2, 247-251.	2.9	0
67	Age-dependent changes in nervonic acid-containing sphingolipids in mouse hippocampus. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 1502-1511.	2.4	43
68	Identification of a Widespread Palmitoylethanolamide Contamination in Standard Laboratory Glassware. Cannabis and Cannabinoid Research, 2017, 2, 123-132.	2.9	15
69	A Guide to the National Academy of Science Report on Cannabis: An Exclusive Discussion with Panel Members. Cannabis and Cannabinoid Research, 2017, 2, 155-159.	2.9	8
70	Patch clamp-assisted single neuron lipidomics. Scientific Reports, 2017, 7, 5318.	3.3	13
71	Complete Acid Ceramidase ablation prevents cancer-initiating cell formation in melanoma cells. Scientific Reports, 2017, 7, 7411.	3.3	49
72	Suppression of acute and anticipatory nausea by peripherally restricted fatty acid amide hydrolase inhibitor in animal models: role of PPARÎ± and CB₁ receptors. British Journal of Pharmacology, 2017, 174, 3837-3847.	5.4	17

#	Article	IF	Citations
73	Synthesis and characterization of the first inhibitor ofN-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). Chemical Communications, 2017, 53, 12814-12817.	4.1	33
74	In Honor of Loren Parsons, PhD. Cannabis and Cannabinoid Research, 2016, 1, 195-195.	2.9	0
75	Medicinal Cannabis in California: An Interview with Igor Grant, MD. Cannabis and Cannabinoid Research, 2016, 1, 78-80.	2.9	0
76	Role of the satiety factor oleoylethanolamide in alcoholism. Addiction Biology, 2016, 21, 859-872.	2.6	58
77	Enhancement of Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social Impairment. Cannabis and Cannabinoid Research, 2016, 1, 81-89.	2.9	81
78	Obesity development in neuron-specific lipoprotein lipase deficient mice is not responsive to increased dietary fat content or change in fat composition. Metabolism: Clinical and Experimental, 2016, 65, 987-997.	3.4	7
79	A simple and accurate protocol for absolute polar metabolite quantification in cell cultures using quantitative nuclear magnetic resonance. Analytical Biochemistry, 2016, 501, 26-34.	2.4	12
80	TheCannabis sativaVersusCannabis indicaDebate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 2016, 1, 44-46.	2.9	99
81	Absolute nutrient concentration measurements in cell culture media: 1H q-NMR spectra and data to compare the efficiency of pH-controlled protein precipitation versus CPMG or post-processing filtering approaches. Data in Brief, 2016, 8, 387-393.	1.0	3
82	Bile Acid Recognition by NAPE-PLD. ACS Chemical Biology, 2016, 11, 2908-2914.	3.4	36
83	Secondâ€Generation Nonâ€Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis. Angewandte Chemie, 2016, 128, 11359-11363.	2.0	4
84	Endogenous N -acyl taurines regulate skin wound healing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4397-406.	7.1	37
85	Secondâ€Generation Nonâ€Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis. Angewandte Chemie - International Edition, 2016, 55, 11193-11197.	13.8	39
86	Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. Scientific Reports, 2016, 6, 31046.	3.3	13
87	Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury. Cannabis and Cannabinoid Research, 2016, 1, 218-228.	2.9	27
88	Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase. Journal of Visualized Experiments, 2016, , .	0.3	2
89	Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structureâ€"Activity Relationships. Synthesis, 2016, 48, 2739-2756.	2.3	4
90	Assay of Monoacylglycerol Lipase Activity. Methods in Molecular Biology, 2016, 1412, 157-168.	0.9	3

#	Article	IF	Citations
91	Acid Ceramidase in Melanoma. Journal of Biological Chemistry, 2016, 291, 2422-2434.	3.4	72
92	Legal or Illegal, Cannabis Is Still Addictive. Cannabis and Cannabinoid Research, 2016, 1, 47-53.	2.9	6
93	Potent Î±-amino-Î²-lactam carbamic acid ester as NAAA inhibitors. Synthesis and structureâ€“activity relationship (SAR) studies. European Journal of Medicinal Chemistry, 2016, 111, 138-159.	5.5	26
94	Introduction to Cannabis and Cannabinoid Research. Cannabis and Cannabinoid Research, 2016, 1, 1-2.	2.9	9
95	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. Journal of Medicinal Chemistry, 2016, 59, 2612-2632.	6.4	70
96	Vaccenic acid suppresses intestinal inflammation by increasing anandamide and related N-acylethanolamines in the JCR:LA-cp rat. Journal of Lipid Research, 2016, 57, 638-649.	4.2	30
97	A role for the endocannabinoid 2-arachidonoyl-sn-glycerol for social and high-fat food reward in male mice. Psychopharmacology, 2016, 233, 1911-1919.	3.1	32
98	Ion mobility mass spectrometry enhances low-abundance species detection in untargeted lipidomics. Metabolomics, 2016, 12, 50.	3.0	36
99	Fluorine nuclear magnetic resonance-based assay in living mammalian cells. Analytical Biochemistry, 2016, 495, 52-59.	2.4	31
100	Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies. European Journal of Medicinal Chemistry, 2016, 109, 216-237.	5.5	28
101	Macrophage-derived lipid agonists of PPAR-Î±as intrinsic controllers of inflammation. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 7-14.	5.2	62
102	Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats. Neuropsychopharmacology, 2016, 41, 1329-1339.	5.4	36
103	Monoglyceride lipase: Structure and inhibitors. Chemistry and Physics of Lipids, 2016, 197, 13-24.	3.2	53
104	A Primary Cortical Input to Hippocampus Expresses a Pathway-Specific and Endocannabinoid-Dependent Form of Long-Term Potentiation. ENeuro, 2016, 3, ENEURO.0160-16.2016.	1.9	65
105	Innentitelbild: Benzoxazolone Carboxamides: Potent and Systemically Active Inhibitors of Intracellular Acid Ceramidase (Angew. Chem. 2/2015). Angewandte Chemie, 2015, 127, 374-374.	2.0	0
106	Modulation of sweet taste sensitivities by endogenous leptin and endocannabinoids in mice. Journal of Physiology, 2015, 593, 2527-2545.	2.9	37
107	Cannabinoids and Endocannabinoids. , 2015, , 1-31.		2
108	Deficiency of Lipoprotein Lipase in Neurons Decreases AMPA Receptor Phosphorylation and Leads to Neurobehavioral Abnormalities in Mice. PLoS ONE, 2015, 10, e0135113.	2.5	13

#	Article	IF	Citations
109	Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. Neuropsychopharmacology, 2015, 40, 2185-2197.	5.4	82
110	Fasting stimulates 2-AG biosynthesis in the small intestine: role of cholinergic pathways. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R805-R813.	1.8	44
111	Structure of Human N -Acylphosphatidylethanolamine-Hydrolyzing Phospholipase D: Regulation of Fatty Acid Ethanolamide Biosynthesis by Bile Acids. Structure, 2015, 23, 598-604.	3.3	77
112	Peroxide-Dependent MGL Sulfenylation Regulates 2-AG-Mediated Endocannabinoid Signaling in Brain Neurons. Chemistry and Biology, 2015, 22, 619-628.	6.0	31
113	Activity-Based Probe for N-Acylethanolamine Acid Amidase. ACS Chemical Biology, 2015, 10, 2057-2064.	3.4	25
114	Feeding-induced oleoylethanolamide mobilization is disrupted in the gut of diet-induced obese rodents. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1218-1226.	2.4	45
115	A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. ACS Chemical Biology, 2015, 10, 1838-1846.	3.4	71
116	Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS. Analytical and Bioanalytical Chemistry, 2015, 407, 5189-5198.	3.7	47
117	Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. Pharmacological Research, 2015, 97, 7-15.	7.1	51
118	Intestinal lipidâ€“derived signals that sense dietary fat. Journal of Clinical Investigation, 2015, 125, 891-898.	8.2	92
119	Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal antiâ€inflammatory drugâ€dependent gastrointestinal damage. FASEB Journal, 2015, 29, 2616-2627.	0.5	57
120	Endocannabinoid signaling mediates oxytocin-driven social reward. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14084-14089.	7.1	163
121	Methamphetamine Accelerates Cellular Senescence through Stimulation of De Novo Ceramide Biosynthesis. PLoS ONE, 2015, 10, e0116961.	2.5	39
122	Effects of Acute Stress on Cardiac Endocannabinoids, Lipogenesis, and Inflammation in Rats. Psychosomatic Medicine, 2014, 76, 20-28.	2.0	20
123	More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology, 2014, 76, 228-234.	4.1	107
124	A Discount on Cannabinoids. Biological Psychiatry, 2014, 75, 432-434.	1.3	1
125	Sample preparation and orthogonal chromatography for broad polarity range plasma metabolomics: Application to human subjects with neurodegenerative dementia. Analytical Biochemistry, 2014, 455, 48-54.	2.4	38
126	Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacological Research, 2014, 86, 11-17.	7.1	54

#	Article	IF	Citations
127	3â€Aminoazetidinâ€2â€one Derivatives as Nâ€Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration. ChemMedChem, 2014, 9, 1602-1614.	3.2	23
128	Synthesis, Structureâ€“Activity, and Structureâ€“Stability Relationships of 2â€Substitutedâ€Nâ€(4â€oxoâ€3â€oxetanyl) Nâ€Acylethanolamine Acid Amidase (NAAA) Inhibitors. ChemMedChem, 2014, 9, 323-336.	3.2	29
129	Peripheral gating of pain signals by endogenous lipid mediators. Nature Neuroscience, 2014, 17, 164-174.	14.8	214
130	Synthesis, Biological Evaluation, and 3D QSAR Study of 2-Methyl-4-oxo-3-oxetanylcarbamic Acid Esters as N-Acylethanolamine Acid Amidase (NAAA) Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 10101-10111.	6.4	13
131	A Lipid Gate for the Peripheral Control of Pain. Journal of Neuroscience, 2014, 34, 15184-15191.	3.6	56
132	Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain. Pharmacological Research, 2014, 87, 87-93.	7.1	11
133	A mighty (ochondrial) fight?. Molecular Metabolism, 2014, 3, 345-346.	6.5	5
134	Synthesis and Structureâ€“Activity Relationship Studies of O-Biphenyl-3-yl Carbamates as Peripherally Restricted Fatty Acid Amide Hydrolase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 5917-5930.	6.4	24
135	Synthesis and Structureâ€“Activity Relationship (SAR) of 2-Methyl-4-oxo-3-oxetanylcarbamic Acid Esters, a Class of Potent N-Acylethanolamine Acid Amidase (NAAA) Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 6917-6934.	6.4	43
136	Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain, 2013, 154, 350-360.	4.2	98
137	Development of a Multigram Synthesis of URB937, a Peripherally Restricted FAAH Inhibitor. Organic Process Research and Development, 2013, 17, 359-367.	2.7	6
138	Quantum Mechanics/Molecular Mechanics Modeling of Fatty Acid Amide Hydrolase Reactivation Distinguishes Substrate from Irreversible Covalent Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 2500-2512.	6.4	35
139	Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Scientific Reports, 2013, 3, 1035.	3.3	133
140	A fatty gut feeling. Trends in Endocrinology and Metabolism, 2013, 24, 332-341.	7.1	175
141	Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. FASEB Journal, 2013, 27, 2513-2520.	0.5	71
142	Peroxisome Proliferator-Activated Receptor Î± Mediates Acute Effects of Palmitoylethanolamide on Sensory Neurons. Journal of Neuroscience, 2012, 32, 12735-12743.	3.6	63
143	Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nature Communications, 2012, 3, 1080.	12.8	234
144	Î²-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. ACS Medicinal Chemistry Letters, 2012, 3, 422-426.	2.8	36

#	Article	IF	Citations
145	The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends in Neurosciences, 2012, 35, 403-411.	8.6	118
146	2-Arachidonoylglycerol Signaling in Forebrain Regulates Systemic Energy Metabolism. Cell Metabolism, 2012, 15, 299-310.	16.2	91
147	A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience, 2012, 15, 64-69.	14.8	150
148	Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. Pharmacological Research, 2012, 65, 553-563.	7.1	81
149	N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis and Structureâ€“Activity and Structureâ€“Property Relationships. Journal of Medicinal Chemistry, 2012, 55, 4824-4836.	6.4	48
150	A thickening network of lipids. Pain, 2012, 153, 3-4.	4.2	6
151	A Catalytic Mechanism for Cysteine N-Terminal Nucleophile Hydrolases, as Revealed by Free Energy Simulations. PLoS ONE, 2012, 7, e32397.	2.5	63
152	The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. Pharmacological Research, 2011, 64, 359-363.	7.1	26
153	Role of endocannabinoids and their analogues in obesity and eating disorders. Eating and Weight Disorders, 2011, 16, e72-e72.	2.5	14
154	Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. Psychopharmacology, 2011, 214, 465-476.	3.1	61
155	Proinflammatory Stimuli ControlN-Acylphosphatidylethanolamine-Specific Phospholipase D Expression in Macrophages. Molecular Pharmacology, 2011, 79, 786-792.	2.3	80
156	Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nature Neuroscience, 2010, 13, 1265-1270.	14.8	289
157	Synthesis and Structureâ^'Activity Relationships of N-(2-Oxo-3-oxetanyl)amides as N-Acylethanolamine-hydrolyzing Acid Amidase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 5770-5781.	6.4	53
158	Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs. International Review of Neurobiology, 2009, 85, 57-72.	2.0	74
159	Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. British Journal of Psychiatry, 2009, 194, 371-372.	2.8	157
160	Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. Journal of Neural Transmission, 2009, 116, 301-305.	2.8	41
161	Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 639-643.	2.2	114
162	The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology, 2009, 56, 235-243.	4.1	90

#	Article	IF	Citations
163	Selective N -acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20966-20971.	7.1	206
164	The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology, 2008, 196, 389-395.	3.1	67
165	Bedside to Bench: The element of surprise. Nature Medicine, 2008, 14, 720-721.	30.7	10
166	Fatty Acid Amide Hydrolase Inhibition Heightens Anandamide Signaling Without Producing Reinforcing Effects in Primates. Biological Psychiatry, 2008, 64, 930-937.	1.3	151
167	The Lipid Messenger OEA Links Dietary Fat Intake to Satiety. Cell Metabolism, 2008, 8, 281-288.	16.2	321
168	Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology, 2008, 22, 262-269.	4.0	45
169	Acute Intracerebroventricular Administration of Palmitoylethanolamide, an Endogenous Peroxisome Proliferator-Activated Receptor-Î± Agonist, Modulates Carrageenan-Induced Paw Edema in Mice. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 1137-1143.	2.5	134
170	Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. Schizophrenia Research, 2007, 94, 29-36.	2.0	219
171	Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress. Biological Psychiatry, 2007, 62, 1103-1110.	1.3	314
172	A neuroscientist's guide to lipidomics. Nature Reviews Neuroscience, 2007, 8, 743-754.	10.2	327
173	Lack of abuse liability of the FAAH inhibitor URB597 in squirrel monkeys. FASEB Journal, 2007, 21, .	0.5	1
174	Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597). CNS Neuroscience & Therapeutics, 2006, 12, 21-38.	4.0	331
175	Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404. Neuropsychopharmacology, 2006, 31, 2652-2659.	5.4	208
176	Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-Î±. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1051-1061.	2.5	299
177	Cold Exposure Stimulates Synthesis of the Bioactive Lipid Oleoylethanolamide in Rat Adipose Tissue. Journal of Biological Chemistry, 2006, 281, 22815-22818.	3.4	29
178	The challenge of brain lipidomics. Prostaglandins and Other Lipid Mediators, 2005, 77, 23-34.	1.9	42
179	The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-Î± Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide. Molecular Pharmacology, 2005, 67, 15-19.	2.3	804
180	The search for the palmitoylethanolamide receptor. Life Sciences, 2005, 77, 1685-1698.	4.3	224

#	Article	IF	Citations
181	Oleoylethanolamide, an endogenous PPAR-Î± agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology, 2005, 48, 1147-1153.	4.1	249
182	QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chemical Communications, 2005, , 4399.	4.1	62
183	The endocannabinoid system: a drug discovery perspective. Current Opinion in Investigational Drugs, 2005, 6, 672-9.	2.3	91
184	Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms. Neuropsychopharmacology, 2004, 29, 2108-2114.	5.4	423
185	Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor Î± (PPAR-Î±). Journal of Biological Chemistry, 2004, 279, 27849-27854.	3.4	295
186	Cyclohexylcarbamic Acid 3â€˜- or 4â€˜-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors:Â Synthesis, Quantitative Structureâ^'Activity Relationships, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2004, 47, 4998-5008.	6.4	255
187	The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology, 2004, 47, 359-367.	4.1	35
188	The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 2003, 4, 873-884.	10.2	1,745
189	Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-Î±. Nature, 2003, 425, 90-93.	27.8	985
190	Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine, 2003, 9, 76-81.	30.7	1,306
191	Design, Synthesis, and Structureâ^'Activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 2352-2360.	6.4	160
192	Modulation of Meal Pattern in the Rat by the Anorexic Lipid Mediator Oleoylethanolamide. Neuropsychopharmacology, 2003, 28, 1311-1316.	5.4	144
193	Role of Endogenous Cannabinoids in Synaptic Signaling. Physiological Reviews, 2003, 83, 1017-1066.	28.8	1,399
194	A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chemistry and Physics of Lipids, 2002, 121, 149-158.	3.2	285
195	Role of the endogenous cannabinoid system as a modulator of dopamine transmission: Implications for Parkinsonâ€™s disease and schizophrenia. Neurotoxicity Research, 2001, 3, 23-35.	2.7	54
196	Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. European Journal of Pharmacology, 2001, 419, 191-198.	3.5	219
197	Quantification of Bioactive Acylethanolamides in Rat Plasma by Electrospray Mass Spectrometry. Analytical Biochemistry, 2000, 280, 87-93.	2.4	152
198	Trick or treat from food endocannabinoids?. Nature, 1998, 396, 636-637.	27.8	62

#	Article	IF	Citations
199	Control of pain initiation by endogenous cannabinoids. Nature, 1998, 394, 277-281.	27.8	995
200	Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor,N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain. Journal of Neuroscience, 1997, 17, 1226-1242.	3.6	380
201	A second endogenous cannabinoid that modulates long-term potentiation. Nature, 1997, 388, 773-778.	27.8	1,374
202	Biosynthesis of an Endogenous Cannabinoid Precursor in Neurons and its Control by Calcium and cAMP. Journal of Neuroscience, 1996, 16, 3934-3942.	3.6	289
203	Anandamide Amidohydrolase Activity in Rat Brain Microsomes. Journal of Biological Chemistry, 1995, 270, 6030-6035.	3.4	304